Skip to main content Accessibility help
  • Print publication year: 2011
  • Online publication date: October 2011

Chapter 4 - Neuromuscular disorders


1. CroninS, HardimanO, TraynorBJ. Ethnic variation in the incidence of ALS – a systematic review. Neurology. 2007;68:1002–1007.
2. HaverkampLJ, AppelV, AppelSH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118(3):707–719.
3. BrooksBR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial “Clinical limits of amyotrophic lateral sclerosis” workshop contributors. J Neurol Sci. 1994;124(Suppl):96–107.
4. MillerRG, MitchellJD, LyonM, MooreDH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2007;24:CD001447.
5. Cabrera SerranoM, RabinsteinAA. Causes and outcomes of acute neuromuscular respiratory failure. Arch Neurol. 2010;67(9):1089–1094.
6. MillerRG, JacksonCE, KasarskisEJ, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1218–1226.
7. MillerRG, JacksonCE, KasarskisEJ, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73(15):1227–1233.
8. GonzalezH, OlssonT, BorgK. Management of postpolio syndrome. Lancet Neurol. 2010;9(6):634–642.
9. BorgK. Post-polio muscle dysfunction 29th ENMC workshop 14–16 October 1994, Naarden, the Netherlands. Neuromuscul Disord. 1996;6:75–80.
10. GrimbyG, StalbergE, SandbergA, SunnerhagenKS. An 8-year longitudinal study of muscle strength, muscle fiber size, and dynamic electromyogram in individuals with late polio. Muscle Nerve. 1998;21:1428–1437.
11. GriffinJW, LiCY, HoTW, et al. Guillain-Barre´ syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. Brain. 1995;118:577–595.
12. HughesRA, CornblathDR. Guillain-Barré syndrome. Lancet. 2005;366(9497):1653–1666
13. YukiN, SusukiK, KogaM, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci USA. 2004;101:11404–11409.
14. Van KoningsveldR, SchmitzPIM, van der Meche FGA for the Dutch GBS Study Group. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet. 2004;363:192–196.
15. BansalBC, SoodAK, GuptaAK, YadavP. Role of steroids in the treatment of Guillain-Barre syndrome – a controlled trial. Neurol India. 2004;34:329–335.
16. Plasma Exchange/Sandoglobulin Guillain–Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barre syndrome. Lancet. 1997;349:225–230
17. HughesRA, WijdicksEF, BarohnR, et al. Practice parameter: immunotherapy for Guillain–Barre syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61:736–740.
18. Van den BerghPY, HaddenRD, BoucheP, et al; European Federation of Neurological Societies; Peripheral Nerve Society. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision. Eur J Neurol. 2010;17(3):356–363.
19. MeuthSG, KleinschnitzC. Multifocal motor neuropathy: update on clinical characteristics, pathophysiological concepts and therapeutic options. Eur Neurol. 2010;63(4):193–204.
20. CollinsMP, MendellJR, PeriquetMI, et al. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology. 2000;55(5):636–643.
21. Gorson, KC.Vasculitic neuropathies: an update. Neurologist. 2007;13(1):12–19.
22. SchaublinGA, MichetCJ Jr, DyckPJ, BurnsTM. An update on the classification and treatment of vasculitic neuropathy. Lancet Neurol. 2005;4(12):853–865.
23. MyglandA, LjøstadU, FingerleV, et al. European Federation of Neurological Societies. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. 2010;17(1):8–16, e1–4.
24. ChanYC, LoYL, ChanESY. Immunotherapy for diabetic amyotrophy. Cochrane Database Syst Rev. 2009;3:CD006521.
25. RidleyA. Porphyric neuropathy. In DyckPJ, ThomasPK, LambertEH, BungeR (eds), Peripheral Neuropathy. Philadelphia, PA: Saunders,1984; pp. 1704–1716.
26. SackGH. Acute intermittent porphyria. JAMA. 1990;264(10):1290–1293.
27. LaiwahAC, McCollKE. Management of attacks of acute porphyria. Drugs. 1987;34(5):604–616.
28. WatsonDF, LisakRP. Myasthenia gravis: an overview. In LisakRP (ed), Handbook of Myasthenia Gravis and Myasthenic Syndromes. New York: Marcel Dekker, 1994; pp. 1–21.
29. SkeieGO, ApostolskibS, EvolicA, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17:893–902.
30. SobelJ. Botulism. Clin Infect Dis. 2005;41(8):1167–1173.
31. MisraUK, KalitaJ. Toxic neuropathies. Neurol India. 2009;57(6):697–705
32. DalakasMC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6(3):129–137.
33. KhanFY. Rhabdomyolysis: a review of the literature. Neth J Med. 2009;67(9):272–283.
34. SaagKG. Prevention of glucocorticoid-induced osteoporosis. South Med J. 2004;97:555–558.
35. Van den BergLH, LokhorstH, WokkeJH. Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy. Neurology. 1997;48(4):1135.
36. PestronkA, CornblathDR, IlyasAA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988;24(1):73–78.
37. KorinthenbergR, SchesslJ, KirschnerJ, MöntingJS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics. 2005;116(1):8–14.
38. McDaneldLM, FieldsJD, BourdetteDN, BhardwajA. Immunomodulatory therapies in neurologic critical care. Neurocrit Care. 2010;12(1):132–143.
39. GajdosP, ChevretS, ToykaK. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2008;1:CD002277.
40. HughesR. The role of IVIg in autoimmune neuropathies: the latest evidence. J Neurol. 2008;255(Suppl 3):7–11.
41. GajdosP, ChevretS, ClairB, TranchantC, ChastangC.Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997;41:789–796.
42. LevyY, UzielY, ZandmanG, et al. Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci. 2005;1051:779–786.
43. NattieE. CO2, brainstem chemoreceptors and breathing. Prog Neurobiol. 1999;59(4):299–331.
44. CohenMI, PierceyMF, GootmanPM, WolotskyP. Synaptic connections between medullary inspiratory neurons and phrenic motoneurons as revealed by cross-correlation. Brain Res. 1974;81(2):319–324.
45. BergerAJ, MitchellRA, SeveringhausJW. Regulation of respiration: (second of three parts). New Engl J Med. 1977;297(3):138–143.
46. ChenR. Anatomy and physiology of respiration. In BrownWF, BoltonCF, AminoffMJ (eds), Neuromuscular Function and Disease. Philadelphia, PA: Saunders, 2002; pp. 567–575.
47. KellyBJ, LuceJM. The diagnosis and management of neuromuscular diseases causing respiratory failure. Chest. 1991;99(6):1485–1494.
48. RopperAH, KehneSM. Guillain-Barré syndrome: management of respiratory failure. Neurology. 1985;35(11):1662–1665.
49. MehtaS. Neuromuscular disease causing acute respiratory failure. Respir Care. 2006;51(9):1016–1021.
50. HughesRA, BihariD. Acute neuromuscular respiratory paralysis. J Neurol Neurosurg Ps. 1993;56(4):334–343.
51. RabinsteinAA, WijdicksEF. Warning signs of imminent respiratory failure in neurological patients. Semin Neurol. 2003;23(1):97–104.
52. MeduriGU, ConoscentiCC, MenasheP, et al. Noninvasive face mask ventilation in patients with acute respiratory failure. Chest. 1989;95:865–870.
53. RaccaF, Del SorboL, MonginiT, VianelloA, RanieriVM. Respiratory management of acute respiratory failure in neuromuscular diseases. Minerva Anestesiol. 2010;76(1):51–62.
54. VianelloA, BevilacquaM, ArcaroG, GallanF, SerraE.Non-invasive ventilatory approach to treatment of acute respiratory failure in neuromuscular disorders. A comparison with endotracheal intubation. Intens Care Med. 2000;26(4):384–390.
55. LawnND, FletcherDD, HendersonRD, WolterTD, WijdicksEF. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol. 2001;58(6):893–898.
56. SeneviratneJ, MandrekarJ, WijdicksEF, RabinsteinAA. Noninvasive ventilation in myasthenic crisis. Arch Neurol. 2008;65(1):54–58.
57. WijdicksEF, RoyTK. BiPAP in early Guillain-Barré syndrome may fail. Can J Neurol Sci. 2006;33(1):105–106.